Clinical Cohorts for Validation of New Digital Biomarkers

The MAESTRIA study is an international, multi-centre, non-interventional, observational registry. The main goal is to enrol a representative group of European patients diagnosed with Atrial Fibrillation (AF) to analyse clinical and relevant parameters (digitalised ECG, echocardiograms, cardiac CTs, MRIs and blood biomarkers) that could be used during clinical practise for the diagnosis of atrial cardiomyopathy. The AF patients will be distributed in 3 groups according to the different manifestation of AF: paroxysmal, persistent and permanent AF.

Inclusion Criteria: * Patients with paroxysmal AF, persistent AF or permanent AF. * Patients (or legally acceptable representative if applicable to country specific regulations) provide written informed consent to participate in the study. The patient has the option to give separate consent to donate extra volume of blood during the routine blood collection, that can be used for biomedical research. * Patient is at least 18 years old. * Patient must own a smartphone with Apple iOS version 14.5 (or higher) or with Android version 8.0 (or higher). Exclusion Criteria: * Any disease that limits life expectancy to less than 1 year. * All persons unable to provide informed consent. * All persons exempt from participation in a study or trial by law. * Any medical or psychiatric condition which, in the investigator´s opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.